Recent emerging data indicated that bladder cancers harbouring ATM mutations are susceptible to increased sensitivity to 29 drugs including cisplatin, IGF‐1R inhibitor and BMS‐536924. This evidence concerns the gene IGF1R and urinary bladder carcinoma.